跳至內容

索安非托

維基百科,自由的百科全書
索安非托
臨床資料
商品名英語Drug nomenclatureSunosi
其他名稱SKL-N05, ADX-N05, ARL-N05, YKP10A, R228060, and JZP-110; (R)-2-amino-3-phenylpropylcarbamate hydrochloride
AHFS/Drugs.comMonograph
MedlinePlusa619040
核准狀況
給藥途徑By mouth
藥物類別英語Drug classNorepinephrine–dopamine reuptake inhibitors
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物利用度~95%[2]
血漿蛋白結合率13.3–19.4%[2]
藥物代謝Minimal[2]
生物半衰期~7.1 hours[2]
排泄途徑Urine (95% unchanged)
識別資訊
  • (2R)-2-Amino-3-phenylpropyl carbamate
CAS號178429-62-4
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
化學資訊
化學式C10H14N2O2
摩爾質量194.23 g·mol−1
3D模型(JSmol英語JSmol
  • C1=CC=C(C=C1)C[C@H](COC(=O)N)N
  • InChI=1S/C10H14N2O2/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H2,12,13)/t9-/m1/s1
  • Key:UCTRAOBQFUDCSR-SECBINFHSA-N

索安非托(英語:Solriamfetol,商品名有:Sunosi),也叫索利氨酯,是一種有機化合物,分子式C10H14N2O2,可用於治療睡眠呼吸暫停發作性嗜睡病[2][3][4]

參考文獻

  1. ^ Summary Basis of Decision (SBD) for Sunosi. Health Canada. 23 October 2014 [29 May 2022]. (原始內容存檔於2023-03-06). 
  2. ^ 2.0 2.1 2.2 2.3 2.4 2.5 Sunosi – solriamfetol tablet, film coated. DailyMed. 16 October 2019 [24 November 2019]. (原始內容存檔於2020-08-07). 
  3. ^ Powell J, Piszczatoski C, Garland S. Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea. Ann Pharmacother. October 2020, 54 (10): 1016–1020. PMID 32270686. S2CID 215605290. doi:10.1177/1060028020915537. 
  4. ^ Abad VC, Guilleminault C. Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea. Expert Rev Respir Med. December 2018, 12 (12): 1007–1019. PMID 30365900. S2CID 53106520. doi:10.1080/17476348.2018.1541742. 

外部連結

  • Solriamfetol. Drug Information Portal. U.S. National Library of Medicine. [2023-10-29]. (原始內容存檔於2022-12-05). 
  • Solriamfetol hydrochloride. Drug Information Portal. U.S. National Library of Medicine. [2023-10-29]. (原始內容存檔於2021-08-29).